Clinical Trial Update: SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 in combination with Apatinib and chemotherapy for advanced esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN